GoodRx (NASDAQ:GDRX) Shares Up 7.9%

GoodRx Holdings, Inc. (NASDAQ:GDRX)’s stock price was up 7.9% during trading on Monday . The company traded as high as $8.36 and last traded at $8.32. Approximately 716,445 shares traded hands during mid-day trading, a decline of 50% from the average daily volume of 1,440,848 shares. The stock had previously closed at $7.71.

Analysts Set New Price Targets

GDRX has been the topic of a number of research reports. Morgan Stanley raised their price objective on shares of GoodRx from $7.00 to $9.50 and gave the stock an “equal weight” rating in a report on Monday, June 10th. Royal Bank of Canada raised shares of GoodRx from a “sector perform” rating to an “outperform” rating and increased their price objective for the stock from $8.00 to $10.00 in a research note on Thursday, May 23rd. Raymond James raised GoodRx from a “market perform” rating to an “outperform” rating and set a $10.00 price objective for the company in a research note on Thursday, May 16th. KeyCorp raised GoodRx from a “sector weight” rating to an “overweight” rating and set a $9.00 price objective for the company in a research note on Wednesday, April 10th. Finally, TD Cowen upped their price objective on GoodRx from $14.00 to $16.00 and gave the stock a “buy” rating in a research note on Thursday, May 16th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $9.32.

GoodRx Stock Performance

The company has a debt-to-equity ratio of 1.02, a current ratio of 6.29 and a quick ratio of 6.29. The business has a 50-day simple moving average of $7.82 and a 200-day simple moving average of $7.10. The firm has a market capitalization of $3.10 billion, a PE ratio of -824.18, a P/E/G ratio of 3.87 and a beta of 1.39.

GoodRx (NASDAQ:GDRX) last issued its quarterly earnings data on Thursday, May 9th. The company reported $0.03 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.01). GoodRx had a negative net margin of 0.86% and a positive return on equity of 3.45%. The company had revenue of $197.88 million for the quarter, compared to analysts’ expectations of $196.20 million. Equities research analysts expect that GoodRx Holdings, Inc. will post 0.17 earnings per share for the current fiscal year.

Institutional Investors Weigh In On GoodRx

Several hedge funds and other institutional investors have recently modified their holdings of GDRX. Citigroup Inc. raised its holdings in shares of GoodRx by 301.7% in the third quarter. Citigroup Inc. now owns 7,997 shares of the company’s stock worth $45,000 after buying an additional 6,006 shares during the period. Vanguard Group Inc. grew its stake in GoodRx by 2.1% in the third quarter. Vanguard Group Inc. now owns 8,681,111 shares of the company’s stock worth $48,875,000 after purchasing an additional 177,961 shares in the last quarter. Raymond James & Associates bought a new position in GoodRx in the fourth quarter worth approximately $192,000. Assenagon Asset Management S.A. grew its stake in GoodRx by 7.9% in the fourth quarter. Assenagon Asset Management S.A. now owns 1,349,800 shares of the company’s stock worth $9,044,000 after purchasing an additional 99,072 shares in the last quarter. Finally, International Assets Investment Management LLC bought a new position in GoodRx in the fourth quarter worth approximately $115,000. 63.77% of the stock is currently owned by hedge funds and other institutional investors.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.